메뉴 건너뛰기




Volumn 53, Issue 7, 2018, Pages 979-986

Highlights from the 2017 North American Cystic Fibrosis Conference

Author keywords

antibiotic therapy; clinical trials; cystic fibrosis (CF); lung transplantation

Indexed keywords

IVACAFTOR; TEZACAFTOR;

EID: 85045706615     PISSN: 87556863     EISSN: 10990496     Source Type: Journal    
DOI: 10.1002/ppul.24000     Document Type: Conference Paper
Times cited : (9)

References (22)
  • 1
    • 85048791183 scopus 로고    scopus 로고
    • The 31st Annual North American Cystic Fibrosis Conference, Indiana Convention Center, Indianapolis, Indiana, November 2-4, 2017., Pediatr Pulmonol Suppl
    • The 31st Annual North American Cystic Fibrosis Conference, Indiana Convention Center, Indianapolis, Indiana, November 2-4, 2017. Pediatr Pulmonol Suppl. 2017; 52:S1–S776.
    • (2017) , vol.52 , pp. S1-S776
  • 2
    • 85028719507 scopus 로고    scopus 로고
    • FDA OKs first in vitro route to expanded approval
    • Kingwell K. FDA OKs first in vitro route to expanded approval. Nat Rev Drug Discov. 2017; 16:591–592.
    • (2017) Nat Rev Drug Discov , vol.16 , pp. 591-592
    • Kingwell, K.1
  • 3
    • 85008221944 scopus 로고    scopus 로고
    • Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study
    • Konstan MW, McKone EF, Moss RB, et al. Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study. Lancet Respir Med. 2017; 5:107–118.
    • (2017) Lancet Respir Med , vol.5 , pp. 107-118
    • Konstan, M.W.1    McKone, E.F.2    Moss, R.B.3
  • 4
    • 84943328860 scopus 로고    scopus 로고
    • Sustained benefit from ivacaftor demonstrated by combining clinical trial and cystic fibrosis patient registry data
    • Sawicki GS, McKone EF, Pasta DJ, et al. Sustained benefit from ivacaftor demonstrated by combining clinical trial and cystic fibrosis patient registry data. Am J Respir Crit Care Med. 2015; 192:836–842.
    • (2015) Am J Respir Crit Care Med , vol.192 , pp. 836-842
    • Sawicki, G.S.1    McKone, E.F.2    Pasta, D.J.3
  • 5
    • 0031804609 scopus 로고    scopus 로고
    • Inhibitors of HIV-1 protease: a major success of structure-assisted drug design
    • Wlodawer A, Vondrasek J. Inhibitors of HIV-1 protease: a major success of structure-assisted drug design. Annu Rev Biophys Biomol Struct. 1998; 27:249–284.
    • (1998) Annu Rev Biophys Biomol Struct , vol.27 , pp. 249-284
    • Wlodawer, A.1    Vondrasek, J.2
  • 6
    • 85016073190 scopus 로고    scopus 로고
    • Molecular structure of the human CFTR ion channel
    • e88
    • Liu F, Zhang Z, Csanady L, Gadsby DC, Chen J. Molecular structure of the human CFTR ion channel. Cell. 2017; 169:85–95 e88.
    • (2017) Cell , vol.169 , pp. 85-95
    • Liu, F.1    Zhang, Z.2    Csanady, L.3    Gadsby, D.C.4    Chen, J.5
  • 7
    • 84974623218 scopus 로고    scopus 로고
    • Epithelial tethering of MUC5AC-rich mucus impairs mucociliary transport in asthma
    • Bonser LR, Zlock L, Finkbeiner W, Erle DJ. Epithelial tethering of MUC5AC-rich mucus impairs mucociliary transport in asthma. J Clin Invest. 2016; 126:2367–2371.
    • (2016) J Clin Invest , vol.126 , pp. 2367-2371
    • Bonser, L.R.1    Zlock, L.2    Finkbeiner, W.3    Erle, D.J.4
  • 8
    • 85034765653 scopus 로고    scopus 로고
    • Tezacaftor-Ivacaftor in patients with cystic fibrosis homozygous for phe508del
    • Taylor-Cousar JL, Munck A, McKone EF, et al. Tezacaftor-Ivacaftor in patients with cystic fibrosis homozygous for phe508del. N Engl J Med. 2017; 377:2013–2023.
    • (2017) N Engl J Med , vol.377 , pp. 2013-2023
    • Taylor-Cousar, J.L.1    Munck, A.2    McKone, E.F.3
  • 9
    • 85034732149 scopus 로고    scopus 로고
    • Tezacaftor-ivacaftor in residual-function heterozygotes with cystic fibrosis
    • Rowe SM, Daines C, Ringshausen FC, et al. Tezacaftor-ivacaftor in residual-function heterozygotes with cystic fibrosis. N Engl J Med. 2017; 377:2024–2035.
    • (2017) N Engl J Med , vol.377 , pp. 2024-2035
    • Rowe, S.M.1    Daines, C.2    Ringshausen, F.C.3
  • 10
    • 84920412587 scopus 로고    scopus 로고
    • Cystic Fibrosis Foundation pulmonary guideline. pharmacologic approaches to prevention and eradication of initial Pseudomonas aeruginosa infection
    • Mogayzel PJ, Jr., Naureckas ET, Robinson KA, et al. Cystic Fibrosis Foundation pulmonary guideline. pharmacologic approaches to prevention and eradication of initial Pseudomonas aeruginosa infection. Ann Am Thorac Soc. 2014; 11:1640–1650.
    • (2014) Ann Am Thorac Soc , vol.11 , pp. 1640-1650
    • Mogayzel, P.J.1    Naureckas, E.T.2    Robinson, K.A.3
  • 11
    • 85041129636 scopus 로고    scopus 로고
    • Potent anti-inflammatory and pro-resolving effects of anabasum in a human model of self-resolving acute inflammation
    • [Epub ahead of print]
    • Motwani MP, Bennett F, Norris PC, et al. Potent anti-inflammatory and pro-resolving effects of anabasum in a human model of self-resolving acute inflammation. Clin Pharmacol Ther. 2017. https://doi.org/10.1002/cpt.980. [Epub ahead of print].
    • (2017) Clin Pharmacol Ther
    • Motwani, M.P.1    Bennett, F.2    Norris, P.C.3
  • 12
    • 85028300098 scopus 로고    scopus 로고
    • A low-molecular-weight alginate oligosaccharide disrupts pseudomonal microcolony formation and enhances antibiotic effectiveness
    • Pritchard MF, Powell LC, Jack AA, et al. A low-molecular-weight alginate oligosaccharide disrupts pseudomonal microcolony formation and enhances antibiotic effectiveness. Antimicrob Agents Chemother. 2017; 61. https://doi.org/10.1128/AAC.00762-17
    • (2017) Antimicrob Agents Chemother , vol.61
    • Pritchard, M.F.1    Powell, L.C.2    Jack, A.A.3
  • 13
    • 85016777444 scopus 로고    scopus 로고
    • The antimicrobial effects of the alginate oligomer OligoG CF-5/20 are independent of direct bacterial cell membrane disruption
    • Pritchard MF, Powell LC, Khan S, et al. The antimicrobial effects of the alginate oligomer OligoG CF-5/20 are independent of direct bacterial cell membrane disruption. Sci Rep. 2017; 7:44731.
    • (2017) Sci Rep , vol.7 , pp. 44731
    • Pritchard, M.F.1    Powell, L.C.2    Khan, S.3
  • 14
    • 85014001279 scopus 로고    scopus 로고
    • Inhaled dry powder mannitol in children with cystic fibrosis: a randomised efficacy and safety trial
    • De Boeck K, Haarman E, Hull J, et al. Inhaled dry powder mannitol in children with cystic fibrosis: a randomised efficacy and safety trial. J Cyst Fibros. 2017; 16:380–387.
    • (2017) J Cyst Fibros , vol.16 , pp. 380-387
    • De Boeck, K.1    Haarman, E.2    Hull, J.3
  • 15
    • 84880078608 scopus 로고    scopus 로고
    • Phase 3 randomized study of the efficacy and safety of inhaled dry powder mannitol for the symptomatic treatment of non-cystic fibrosis bronchiectasis
    • Bilton D, Daviskas E, Anderson SD, et al. Phase 3 randomized study of the efficacy and safety of inhaled dry powder mannitol for the symptomatic treatment of non-cystic fibrosis bronchiectasis. Chest. 2013; 144:215–225.
    • (2013) Chest , vol.144 , pp. 215-225
    • Bilton, D.1    Daviskas, E.2    Anderson, S.D.3
  • 16
    • 84878360064 scopus 로고    scopus 로고
    • Pooled analysis of two large randomised phase III inhaled mannitol studies in cystic fibrosis
    • Bilton D, Bellon G, Charlton B, et al. Pooled analysis of two large randomised phase III inhaled mannitol studies in cystic fibrosis. J Cyst Fibros. 2013; 12:367–376.
    • (2013) J Cyst Fibros , vol.12 , pp. 367-376
    • Bilton, D.1    Bellon, G.2    Charlton, B.3
  • 17
    • 84858234304 scopus 로고    scopus 로고
    • Long-term inhaled dry powder mannitol in cystic fibrosis: an international randomized study
    • Aitken ML, Bellon G, De Boeck K, et al. Long-term inhaled dry powder mannitol in cystic fibrosis: an international randomized study. Am J Respir Crit Care Med. 2012; 185:645–652.
    • (2012) Am J Respir Crit Care Med , vol.185 , pp. 645-652
    • Aitken, M.L.1    Bellon, G.2    De Boeck, K.3
  • 18
    • 84994411660 scopus 로고    scopus 로고
    • Exposing the three-dimensional biogeography and metabolic states of pathogens in cystic fibrosis sputum via hydrogel embedding, clearing, and rRNA labeling
    • DePas WH, Starwalt-Lee R, Van Sambeek L, Ravindra Kumar S, Gradinaru V, Newman DK. Exposing the three-dimensional biogeography and metabolic states of pathogens in cystic fibrosis sputum via hydrogel embedding, clearing, and rRNA labeling. MBio. 2016; 7.
    • (2016) MBio , vol.7
    • DePas, W.H.1    Starwalt-Lee, R.2    Van Sambeek, L.3    Ravindra Kumar, S.4    Gradinaru, V.5    Newman, D.K.6
  • 19
    • 84958211439 scopus 로고    scopus 로고
    • US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis
    • Floto RA, Olivier KN, Saiman L, et al. US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis. Thorax. 2016; 71:i1–i22.
    • (2016) Thorax , vol.71 , pp. i1-i22
    • Floto, R.A.1    Olivier, K.N.2    Saiman, L.3
  • 20
    • 84958206254 scopus 로고    scopus 로고
    • International committee on mental health in cystic fibrosis: cystic fibrosis foundation and european cystic fibrosis society consensus statements for screening and treating depression and anxiety
    • Quittner AL, Abbott J, Georgiopoulos AM, et al. International committee on mental health in cystic fibrosis: cystic fibrosis foundation and european cystic fibrosis society consensus statements for screening and treating depression and anxiety. Thorax. 2016; 71:26–34.
    • (2016) Thorax , vol.71 , pp. 26-34
    • Quittner, A.L.1    Abbott, J.2    Georgiopoulos, A.M.3
  • 21
    • 78650858488 scopus 로고    scopus 로고
    • Collaborative care for patients with depression and chronic illnesses
    • Katon WJ, Lin EH, Von Korff M, et al. Collaborative care for patients with depression and chronic illnesses. N Engl J Med. 2010; 363:2611–2620.
    • (2010) N Engl J Med , vol.363 , pp. 2611-2620
    • Katon, W.J.1    Lin, E.H.2    Von Korff, M.3
  • 22
    • 84896514136 scopus 로고    scopus 로고
    • The interdependent roles of patients, families and professionals in cystic fibrosis: a system for the coproduction of healthcare and its improvement
    • Sabadosa KA, Batalden PB. The interdependent roles of patients, families and professionals in cystic fibrosis: a system for the coproduction of healthcare and its improvement. BMJ Qual Saf. 2014; 23:i90–i94.
    • (2014) BMJ Qual Saf , vol.23 , pp. i90-i94
    • Sabadosa, K.A.1    Batalden, P.B.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.